MA40535A - Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 - Google Patents
Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90Info
- Publication number
- MA40535A MA40535A MA040535A MA40535A MA40535A MA 40535 A MA40535 A MA 40535A MA 040535 A MA040535 A MA 040535A MA 40535 A MA40535 A MA 40535A MA 40535 A MA40535 A MA 40535A
- Authority
- MA
- Morocco
- Prior art keywords
- hsp90
- therapy
- inflammation
- infection
- infection imaging
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0275—Measuring blood flow using tracers, e.g. dye dilution
- A61B5/02755—Radioactive tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0813—Measurement of pulmonary parameters by tracers, e.g. radioactive tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4222—Evaluating particular parts, e.g. particular organs
- A61B5/4255—Intestines, colon or appendix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/44—Constructional features of apparatus for radiation diagnosis
- A61B6/4417—Constructional features of apparatus for radiation diagnosis related to combined acquisition of different diagnostic modalities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5288—Devices using data or image processing specially adapted for radiation diagnosis involving retrospective matching to a physiological signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/54—Control of apparatus or devices for radiation diagnosis
- A61B6/541—Control of apparatus or devices for radiation diagnosis involving acquisition triggered by a physiological signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1884—Nanotubes, nanorods or nanowires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- High Energy & Nuclear Physics (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
Abstract
L'invention concerne de nouvelles méthodes d'imagerie d'une inflammation et d'une infection et des applications médicales associées. Dans certains modes de réalisation, l'invention concerne une méthode pour diagnostiquer une inflammation et/ou une infection. Dans certains modes de réalisation, l'invention concerne une méthode pour traiter ou prévenir l'inflammation et/ou l'infection. Dans certains modes de réalisation, la présente invention concerne des méthodes permettant de surveiller l'effet du traitem
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462051590P | 2014-09-17 | 2014-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40535A true MA40535A (fr) | 2016-03-24 |
Family
ID=55533863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040535A MA40535A (fr) | 2014-09-17 | 2015-09-17 | Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 |
Country Status (12)
Country | Link |
---|---|
US (3) | US10617772B2 (fr) |
EP (1) | EP3194975A4 (fr) |
JP (1) | JP6835709B2 (fr) |
KR (1) | KR20170052687A (fr) |
CN (2) | CN107110869B (fr) |
AU (2) | AU2015317632B2 (fr) |
BR (1) | BR112017005313A2 (fr) |
CA (1) | CA2961499A1 (fr) |
EA (1) | EA201790444A1 (fr) |
MA (1) | MA40535A (fr) |
MX (1) | MX2017003513A (fr) |
WO (1) | WO2016044629A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012282903A1 (en) | 2011-07-08 | 2014-02-13 | Sloan-Kettering Institute For Cancer Research | Uses of labeled HSP90 inhibitors |
BR112016014758A8 (pt) | 2013-12-23 | 2020-06-02 | Memorial Sloan Kettering Cancer Center | composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto |
MX2017003513A (es) * | 2014-09-17 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. |
WO2018048882A1 (fr) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Composition d'agent d'imagerie par tomographie par imagerie de positrons et méthode pour infection bactérienne |
SG11201908670SA (en) | 2017-03-20 | 2019-10-30 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
EP3852791B1 (fr) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activation de la pyruvate kinase r |
CN113166060B (zh) | 2018-09-19 | 2024-01-09 | 诺沃挪第克健康护理股份公司 | 用丙酮酸激酶激活化合物治疗镰状细胞病 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1437145A1 (fr) * | 2003-01-07 | 2004-07-14 | Schering AG | Agents scintigraphiques améliorés pour l'imagerie des infections et inflammations |
CA2524072A1 (fr) | 2003-05-01 | 2004-11-11 | University Of Liverpool | Procede de criblage permettant l'identification de modulateurs de hsp90 |
BRPI0414533A (pt) | 2003-09-18 | 2006-11-07 | Conforma Therapeutics Corp | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 |
US7834181B2 (en) * | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
WO2006098761A2 (fr) | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants |
EP1879863A1 (fr) | 2005-05-03 | 2008-01-23 | Pfizer, Inc. | Composes d'amide resorcinol |
US20090215777A1 (en) | 2005-05-19 | 2009-08-27 | Astex Therapeutics Ltd. | Pyrimidine Derivatives As HSP90 Inhibitors |
WO2006130469A1 (fr) * | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation de la croissance des neurites au moyen de molecules de petite taille |
EP2007767B1 (fr) | 2006-03-11 | 2011-11-02 | Vernalis (R&D) Ltd | Derives de pyrrolopyrimidine en tant qu'inhibiteurs de hsp90 |
CN101490052B (zh) | 2006-05-12 | 2012-08-08 | 美瑞德生物工程公司 | 治疗性化合物及其在癌症中的用途 |
DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
EP2034839B1 (fr) * | 2006-06-30 | 2017-08-23 | Sloan-Kettering Institute for Cancer Research | Traitement de maladies neurodégénératives par l'inhibition de hsp90 |
WO2008093075A2 (fr) | 2007-02-01 | 2008-08-07 | Astrazeneca Ab | Dérivés de 5,6,7,8-tétrahydroptéridine comme inhibiteurs de hsp90 |
MY148860A (en) | 2007-03-20 | 2013-06-14 | Curis Inc | Fused amino pyridine as hsp90 inhibitors |
US8524712B2 (en) | 2007-03-27 | 2013-09-03 | Synta Pharmaceuticals Corp. | Triazinone and diazinone derivatives useful as HSP90 inhibitors |
SG187502A1 (en) | 2008-02-01 | 2013-02-28 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors |
FR2932484B1 (fr) | 2008-06-16 | 2010-06-18 | Sanofi Aventis | Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation |
RU2011126254A (ru) | 2008-11-28 | 2013-01-10 | Новартис Аг | Применение ингибтиторов hsp90 для терапевтического лечения |
ES2533954T3 (es) | 2009-04-21 | 2015-04-16 | Nerviano Medical Sciences S.R.L. | Derivados de resorcinol como inhibidores de HSP90 |
BR112012003637A2 (pt) | 2009-08-17 | 2017-04-25 | Memorial Sloan Kettering Cancer Center | "compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos" |
JP5941407B2 (ja) | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Hsp90阻害剤 |
WO2011060253A2 (fr) | 2009-11-13 | 2011-05-19 | Myrexis, Inc. | Méthodes de traitement de maladies, composés pharmaceutiques, compositions et formes pharmaceutiques |
US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
US8669248B1 (en) * | 2010-09-30 | 2014-03-11 | John Montana | Adenine inhibitors of HSP90 |
EP2694505B1 (fr) * | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Inhibiteurs de la hsp90 |
EP2694506B1 (fr) * | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Inhibiteurs de hsp90 |
US8685966B2 (en) * | 2011-04-08 | 2014-04-01 | University Of Kansas | GRP94 inhibitors |
KR102196424B1 (ko) | 2011-04-28 | 2020-12-30 | 슬로안-케테링인스티튜트퍼캔서리서치 | Hsp90 병용요법 |
AU2012282903A1 (en) | 2011-07-08 | 2014-02-13 | Sloan-Kettering Institute For Cancer Research | Uses of labeled HSP90 inhibitors |
CN102319240A (zh) * | 2011-07-19 | 2012-01-18 | 厦门大学 | 去乙酰真菌环氧乙酯作为Hsp90抑制剂的应用 |
US9738643B2 (en) * | 2012-08-06 | 2017-08-22 | Duke University | Substituted indazoles for targeting Hsp90 |
WO2014144715A1 (fr) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Imagerie cardiaque à ciblage hsp90 et traitement associé |
CA2921571C (fr) * | 2013-08-16 | 2022-04-05 | Memorial Sloan-Kettering Cancer Center | Inhibiteurs selectifs de la grp94 et leurs utilisations |
BR112016014758A8 (pt) * | 2013-12-23 | 2020-06-02 | Memorial Sloan Kettering Cancer Center | composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto |
EP3131586A4 (fr) * | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Agents thérapeutiques cibles |
MX2017003513A (es) * | 2014-09-17 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. |
-
2015
- 2015-09-17 MX MX2017003513A patent/MX2017003513A/es unknown
- 2015-09-17 MA MA040535A patent/MA40535A/fr unknown
- 2015-09-17 US US15/511,701 patent/US10617772B2/en not_active Expired - Fee Related
- 2015-09-17 BR BR112017005313A patent/BR112017005313A2/pt not_active Application Discontinuation
- 2015-09-17 KR KR1020177010291A patent/KR20170052687A/ko not_active Application Discontinuation
- 2015-09-17 WO PCT/US2015/050753 patent/WO2016044629A1/fr active Application Filing
- 2015-09-17 AU AU2015317632A patent/AU2015317632B2/en not_active Ceased
- 2015-09-17 CN CN201580062252.XA patent/CN107110869B/zh not_active Expired - Fee Related
- 2015-09-17 EP EP15841981.2A patent/EP3194975A4/fr not_active Withdrawn
- 2015-09-17 EA EA201790444A patent/EA201790444A1/ru unknown
- 2015-09-17 CA CA2961499A patent/CA2961499A1/fr active Pending
- 2015-09-17 JP JP2017514812A patent/JP6835709B2/ja active Active
- 2015-09-17 CN CN202110835845.2A patent/CN113521314A/zh active Pending
-
2020
- 2020-04-10 US US16/845,372 patent/US11065350B2/en active Active
-
2021
- 2021-06-16 US US17/349,723 patent/US20210308285A1/en not_active Abandoned
-
2022
- 2022-04-07 AU AU2022202337A patent/AU2022202337A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3194975A4 (fr) | 2018-05-02 |
JP2017530961A (ja) | 2017-10-19 |
EA201790444A1 (ru) | 2017-08-31 |
EP3194975A1 (fr) | 2017-07-26 |
CN107110869A (zh) | 2017-08-29 |
CN107110869B (zh) | 2021-08-10 |
MX2017003513A (es) | 2017-07-28 |
WO2016044629A1 (fr) | 2016-03-24 |
AU2015317632A1 (en) | 2017-04-13 |
US20210308285A1 (en) | 2021-10-07 |
AU2022202337A1 (en) | 2022-04-28 |
US20200237934A1 (en) | 2020-07-30 |
CA2961499A1 (fr) | 2016-03-24 |
BR112017005313A2 (pt) | 2017-12-05 |
AU2015317632B2 (en) | 2022-01-13 |
US11065350B2 (en) | 2021-07-20 |
JP6835709B2 (ja) | 2021-02-24 |
US10617772B2 (en) | 2020-04-14 |
KR20170052687A (ko) | 2017-05-12 |
CN113521314A (zh) | 2021-10-22 |
US20170304470A1 (en) | 2017-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502154A1 (en) | Methods for conditioning patients for t cell therapy | |
EP3641644A4 (fr) | Système et procédé de diagnostic médical | |
EP3622407A4 (fr) | Systèmes et méthodes de traitement de patients | |
EP3649962A4 (fr) | Dispositif médical et procédé de traitement | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
GB2544906B (en) | Devices for treating vestibular and other medical impairments. | |
MX2016010677A (es) | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. | |
MX2018015184A (es) | Métodos para el diagnóstico de infecciones bacterianas y virales. | |
EP3294106A4 (fr) | Dispositifs, procédés et systèmes permettant d'acquérir des informations de diagnostic médical et permettant la fourniture de services de santé à distance | |
MA40535A (fr) | Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 | |
EP3505091A4 (fr) | Dispositif médical et méthode thérapeutique | |
EP3053619A4 (fr) | Seringue médicale, joint utilisé pour une seringue et son procédé de fabrication | |
EP3258849A4 (fr) | Dispositif de filtration d'une pompe médicale, ses procédés de fabrication et d'utilisation | |
GB2541571A (en) | Pharmaceutical compositions | |
EP3452990A4 (fr) | Systèmes et procédés de génération de diagnostics médicaux | |
EP3155971A4 (fr) | Dispositif de diagnostic médical, procédé de fonctionnement d'un dispositif de diagnostic médical et programme de fonctionnement d'un dispositif de diagnostic médical | |
EP3505068A4 (fr) | Dispositif de diagnostic médical et procédé de diagnostic médical l'utilisant | |
EP3275393A4 (fr) | Dispositif d'observation médicale, dispositif d'observation chirurgicale et système d'observation médicale | |
EP3398633A4 (fr) | Système de conception de dispositif d'administration, système d'administration, procédé de conception de dispositif d'administration, programme de conception de dispositif d'administration et système de conception de dispositif médical | |
EP3347844A4 (fr) | Procédé et système pour diagnostiquer une maladie et générer des recommandations de traitement | |
MX2017000141A (es) | Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas. | |
EP3132420A4 (fr) | Appareil d'imagerie médicale et son procédé de fonctionnement | |
EP3520724A4 (fr) | Dispositif médical et méthode thérapeutique | |
EP3508148A4 (fr) | Dispositif médical et méthode thérapeutique | |
EP3590438A4 (fr) | Dispositif de commande d'affichage médical, dispositif d'observation médicale, procédé de commande d'affichage et système d'observation médicale |